3Sarnak M J, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm[J]. Am J Kidney Dis, 2000, 35 (4 Suppl 1):S117-131.
4Virtanen VK, Saha HH, Groundstroem KW, et al. Calcium infusion and left ventricular diastolic function in patients with chronic renal failure[J]. Nephrol Dial Transplant,1998,13(2): 384-388.
5Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? [J]. Kidney Int,2001 ,59(2):407-414.
6Brancaccio D, Tetta C, Gallieni M, et al. Inflammation, CRP, calcium overload and a high calcium-phosphate product: a "liaison dangereuse"[J]. Nephrol Dial Transplant,2002, 17 (2) :201-203.
7Himmelfarb J,Stenvinkel P,Ikizler TA, et al. The elephant in uremia:oxidant stress as a unifying concept of cardiovascular disease in uremia[J]. Kidney Int,2002,62(5):1524-1538.
8Rasic S, Kulenovic I. Haracic A, et al. Left ventricular hypertrophy and risk factors for its development in uraemic patients[J]. BOSh J Basic Med Sci,2004,4(1) :34-40.
9Zile RM,Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part Ⅱ: causal mechanisms and treatment[J]. Circulation ,2002,105( 12) : 1503-1508.
10Afshinnia F, Spitalewitz S, Chou SY, et al.Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure[J]. Am J Kidney Dis, 2007,49(2) : 227- 236.
5Vesa K Virtsnen, Heikki HT Saha, Kaj WE. Groundstroem,et al. Calcium infusion and left ventricular diastolic function in patients with chronic renal failure[ J]. Nephrol Dial Tran,1999,13(2) :384 - 388.
6Hans R,Brunner. Experimental and clinical evidence that angiontensin Ⅱ is an independent risk factor for cardiovascullar disease[ J] .Am J Cardiology,2001,87(8):3- 9.
7Watanabe K, Aizawa Y, Shibata A,et al.Depression of heart funcyion after angiotensin Ⅱ infusion in patients on chronic hemodialysis[ J] .Clin Exp Dial Apheresis, 1981,5(4) :249-259.
8Sadoshima J, Izumo S. Molecular characterization angiotensin Ⅱ- induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype[J]. Circ Res, 1993(3) :412 - 423.
9Kerstin Amann, Peter Gassmann, Moriz Buzello, et al. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rat[J] .Kidney Int,2000,58(1):153-161.
10Valerie Robert, Christophe Heymes,Jea- Sebastien Slivestre,et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone[J]. Hypertension, 1999,33(4) :981 - 986.
